Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557029 | 0.91 | KMT2A (0.35) | KMT2ALMNAAGBL2ALDH1A1KDM4E | |
| SCHEMBL24674722 | 0.81 | ALDH1A1 (0.38) | KMT2ALMNAAGBL2ALDH1A1KDM4E | |
| SCHEMBL20576368 | 0.79 | ALOX5AP (0.40) | KMT2ALMNAAGBL2ALDH1A1KDM4E | |
| SCHEMBL4522170 | 0.78 | HPGD (0.47) | KMT2AAGBL2ALDH1A1KDM4EMAPT | |
| SCHEMBL4522166 | 0.78 | HPGD (0.47) | KMT2AAGBL2ALDH1A1KDM4EMAPT | |
| SCHEMBL3260035 | 0.78 | LMNA (0.42) | KMT2ALMNAALDH1A1KDM4EPOLB | |
| SCHEMBL29955340 | 0.78 | ALOX5AP (0.42) | KMT2ALMNAAGBL2ALDH1A1KDM4E | |
| SCHEMBL22105601 | 0.75 | ERN1 (0.48) | AGBL2ERN1 | |
| SCHEMBL29956834 | 0.75 | ERN1 (0.48) | AGBL2ERN1 | |
| SCHEMBL28641181 | 0.74 | ALDH1A1 (0.47) | KMT2AAGBL2ALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759743-B2 | Pd-catalyzed γ-C(sp3)-H arylation / heteroarylation of free amines | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190241508-A1 | PD-CATALYZED GAMMA-C(SP3)-H ARYLATION / HETEROARYLATION OF FREE AMINES | THE SCRIPPS RESEARCH INSTITUTE | 2019-08-08 | — | — | US | disclosed |
| US-7786305-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786305-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7700772-B2 | Amino heterocyclic modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700772-B2 | Amino heterocyclic modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7589085-B2 | Tetrahydropyran heterocyclic cyclopentyl heteroaryl modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7230008-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
| EP-1746997-A2 | 3-(4-HETEROARYLCYCLOHEXYLAMINO) CZCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2006122200-A1 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
| WO-2005115392-A2 | 3-(4-HETEROARYLCYCLOHEXYLAMINO) CYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2005-12-01 | — | — | US | disclosed |
| EP-1592689-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069162-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | KMT2A 2548/4885LMNA 3093/4885AGBL2 76/4885 |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | KMT2A 3816/4885LMNA 4599/4885AGBL2 1282/4885 |
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | KMT2A 4346/4885LMNA 4529/4885AGBL2 4415/4885 |
| US-10759743-B2 | Pd-catalyzed γ-C(sp3)-H arylation / heteroarylation of free amines | DBH, GRIA3, H1-3 | KMT2A 940/4885LMNA 1794/4885AGBL2 4225/4885 |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | CCR5, CXCR3, CCR2 | KMT2A 4312/4885LMNA 4772/4885AGBL2 1819/4885 |
| US-20190241508-A1 | PD-CATALYZED GAMMA-C(SP3)-H ARYLATION / HETEROARYLATION OF FREE AMINES | DBH, SNCA, H1-3 | KMT2A 975/4885LMNA 1824/4885AGBL2 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.